Dee Czaykowski

As the head of pioneer portfolio initiatives at GSK Dee established a new group designed to prospectively evaluate the pipeline and develop an objective view of future strategic alternatives to current development and commercialisation efforts.

This was after she had developed the vision for and built the global early commercial strategy organization of 30 director level matrix team leaders. Dee designed the strategy generation process, built capabilities, processes and organization infrastructure for the group that partners with R&D to lead the development of Global Commercial Strategy for assets across 9 therapeutic areas and 26 Discovery Units. She was accountable for the early stage global commercial organization which supports the Discovery Units to bring forward medicines of value. Responsible for overseeing all aspects of the commercial process from early stage strategy (disease area and asset-specific) to Phase 2b Medicine Development in effort to optimize investment decisions.

With a career that also included a number of key roles at Pfizer, Dee brings first class Life Sciences credentials – her Wharton School MBA underpins her impressive career achievements.